{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-013413","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.098226+00:00","generated_at":"2026-05-23T04:23:27.389093+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy","bullets":["First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.","Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.","CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-013413","json":"https://secwatch.observer/filing/0001437749-25-013413.json","markdown":"https://secwatch.observer/filing/0001437749-25-013413.md","text":"https://secwatch.observer/filing/0001437749-25-013413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/0001437749-25-013413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/apyx20250428_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:23:27.389093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}